Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 6/20 | 1.00 |
| ▸ | MAOB | P27338 | 10/20 | 0.83 |
| ▸ | MAOA | P21397 | 9/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CES1 | P23141 | 4/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Methoxyisatin SCHEMBL21602 | 0.85 | ALDH1A1 (1.00) | TGM2MAOBMAOAALDH1A1CES1 | |
| 5-Methoxyisatin SCHEMBL29506298 | 0.85 | ALDH1A1 (1.00) | TGM2MAOBMAOAALDH1A1CES1 | |
| SCHEMBL23385135 | 0.84 | TGM2 (0.71) | TGM2MAOBMAOAALDH1A1CES1 | |
| SCHEMBL5697136 | 0.84 | TGM2 (1.00) | TGM2MAOBMAOAALDH1A1CES1 | |
| 5-Methoxyisatin SCHEMBL3935863 | 0.83 | ALDH1A1 (0.96) | TGM2MAOBMAOAALDH1A1CES1 | |
| SCHEMBL1075112 | 0.81 | TGM2 (0.67) | TGM2MAOBMAOAALDH1A1CES1 | |
| SCHEMBL2372943 | 0.80 | ALDH1A1 (0.68) | TGM2MAOBMAOAALDH1A1CES1 | |
| SCHEMBL457929 | 0.80 | CES1 (1.00) | TGM2MAOBMAOAALDH1A1CES1 | |
| SCHEMBL4627666 | 0.80 | TGM2 (0.67) | TGM2MAOBMAOAALDH1A1CES1 | |
| SCHEMBL29475283 | 0.80 | CES1 (1.00) | TGM2MAOBMAOAALDH1A1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362579-B1 | Agent for dyeing keratinous fibres | HENKEL KGAA (DE) | 2006-05-24 | — | — | EP | claimed |
| EP-1362579-A1 | Agent for dyeing keratinous fibres | Henkel Kommanditgesellschaft auf Aktien (DE) | 2003-11-19 | — | — | EP | claimed |
| US-20250101200-A1 | POLYMERIC MATERIALS WITH REDUCED ALDEHYDE CONTENT AND PROCESS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2025-03-27 | — | — | US | disclosed |
| EP-4473037-A1 | POLYMERIC MATERIALS WITH REDUCED ALDEHYDE CONTENT AND PROCESS | Colormatrix Holdings, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118591578-A | Polymeric materials and methods with reduced aldehyde content | 彩色矩阵控股公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023144607-A1 | POLYMERIC MATERIALS WITH REDUCED ALDEHYDE CONTENT AND PROCESS | COLORMATRIX HOLDINGS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023144607-A1 | POLYMERIC MATERIALS WITH REDUCED ALDEHYDE CONTENT AND PROCESS | COLORMATRIX HOLDINGS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (LV) | 2011-03-24 | — | — | US | disclosed |
| EP-2274280-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | Biolipox AB (SE) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009127822-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2009-10-22 | — | — | WO | disclosed |
| US-20090220554-A1 | Transglutaminase Inhibitors and Methods of Use Thereof | PHARMIX CORPORATION | 2009-09-03 | — | — | US | disclosed |
| US-20090220554-A1 | Transglutaminase Inhibitors and Methods of Use Thereof | PHARMIX CORPORATION | 2009-09-03 | — | — | US | disclosed |
| US-20090220554-A1 | Transglutaminase Inhibitors and Methods of Use Thereof | PHARMIX CORPORATION | 2009-09-03 | — | — | US | disclosed |
| EP-1954285-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | Alvine Pharmaceuticals, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007050795-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | ALVINE PHARMACEUTICALS, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| EP-1362579-B1 | Agent for dyeing keratinous fibres | HENKEL KGAA (DE) | 2006-05-24 | — | — | EP | disclosed |
| EP-1362579-A1 | Agent for dyeing keratinous fibres | Henkel Kommanditgesellschaft auf Aktien (DE) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | LTC4S, LTB4R2, LTB4R | TGM2 2255/4885MAOB 57/4885MAOA 131/4885 |
| US-20090220554-A1 | Transglutaminase Inhibitors and Methods of Use Thereof | TGM2, TGM3, TGM1 | TGM2 1/4885MAOB 267/4885MAOA 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.